Telomere length in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 52, Issue 8, 2011, Pages 1528-1536

  Rollison, Dana E ^a   Epling Burnette, P K ^a   Park, Jong Y ^a   Lee, Ji Hyun ^a   Park, Hyun ^a   Jonathan, Kristen ^a   Cole, Ashley L ^a   Painter, Jeffrey S ^a   Guerrier, Mayenha ^a   Meléndez Santiago, Johana ^a   Fulp, William ^a   Komrokji, Rami ^a   Lancet, Jeffrey ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

hTERT; Myelodysplastic syndromes; telomere length

Indexed keywords

CD15 ANTIBODY; CD19 ANTIBODY; CELL ANTIBODY; DNA; PAINT; PESTICIDE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW CELL; CAUSAL ATTRIBUTION; CHROMOSOME SIZE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALIVA; SEX RATIO; TELOMERE LENGTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD15; ANTIGENS, CD19; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENOTYPE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKOCYTES; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PAINT; PESTICIDES; POLYMERASE CHAIN REACTION; SALIVA; TELOMERASE; TELOMERE; YOUNG ADULT;

EID: 79960396259     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.568648     Document Type: Article

References (38)

1. Baird DM, Kipling D. The extent and significance of telomere loss with age. Ann NY Acad Sci 2004;1019:265-268 (Pubitemid 38951317)
2. Londono-Vallejo JA. Telomere length heterogeneity and chromosome instability. Cancer Lett 2004;212:135-144 (Pubitemid 38997969)
3. Boultwood J, Fidler C, Kusec R, et al. Telomere length in myelodysplastic syndromes. Am J Hematol 1997;56:266-271 (Pubitemid 127471680)
4. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000;95:1883-1890 (Pubitemid 30151622)
5. Ohyashiki JH, Iwama H, Yahata N, et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 1999;5:1155-1160 (Pubitemid 29233232)
6. Rigolin GM, Porta MD, Bugli AM, et al. Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinicalbiological findings. Eur J Haematol 2004;73:351-358 (Pubitemid 39349916)
7. Sashida G, Ohyashiki JH, Nakajima A, et al. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 2003;9:1489-1496 (Pubitemid 36418406)
8. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211-1218 (Pubitemid 37069551)
9. Shen J, Terry MB, Gurvich I, Liao Y, Senie RT, Santella RM. Short telomere length and breast cancer risk: a study in sister sets. Cancer Res 2007;67:5538-5544 (Pubitemid 46997296)
10. Mirabello L, Garcia-Closas M, Cawthon R, et al. Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes Control 2010; 21:77-82
11. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007;16: 815-819 (Pubitemid 46650587)
12. Jang JS, Choi YY, Lee WK, et al. Telomere length and the risk of lung cancer. Cancer Sci 2008;99:1385-1389 (Pubitemid 351761728)
13. Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA 2009;106:1187-1192
14. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009;361:2353-2365
15. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413-1424 (Pubitemid 40471449)
16. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849
17. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302
18. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998;83:358-368 (Pubitemid 28217858)
19. Tarone RE, Alavanja MC, Zahm SH, et al. The Agricultural Health Study: factors affecting completion and return of selfadministered questionnaires in a large prospective cohort study of pesticide applicators. Am J Ind Med 1997;31:233-242 (Pubitemid 27063168)
20. Rogers NL, Cole SA, Lan HC, Crossa A, Demerath EW. New saliva DNA collection method compared to buccal cell collection techniques for epidemiological studies. Am J Hum Biol 2007;19:319-326 (Pubitemid 46839443)
21. Rylander-Rudqvist T, Hakansson N, Tybring G, Wolk A. Quality and quantity of saliva DNA obtained from the selfadministrated oragene method-a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev 2006;15: 1742-1745 (Pubitemid 44497113)
22. Cawthon RM, Smith KR, O?Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003;361:393-395 (Pubitemid 36164975)
23. Schmid I, Dagarag MD, Hausner MA, et al. Simultaneous flow cytometric analysis of two cell surface markers, telomere length, and DNA content. Cytometry 2002;49:96-105 (Pubitemid 41202161)
24. Kapoor V, Hakim FT, Rehman N, Gress RE, Telford WG. Quantum dots thermal stability improves simultaneous phenotype-specific telomere length measurement by FISHflow cytometry. J Immunol Methods 2009;344:6-14
25. Vindelov LL, Christensen IJ, Nissen NI. Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 1983;3:328-331 (Pubitemid 13087610)
26. Wang L, Soria JC, Chang YS, Lee HY, Wei Q, Mao L. Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. Oncogene 2003; 22:7123-7129 (Pubitemid 37378544)
27. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009;27: 791-798
28. Marcondes AM, Bair S, Rabinovitch PS, Gooley T, Deeg HJ, Risques R. No telomere shortening in marrow stroma from patients with MDS. Ann Hematol 2009;88:623-628
29. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood 2008;111:4446-4455
30. Calado RT. Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program 2009;338-343
31. Yamaguchi H.Mutations of telomerase complex genes linked to bone marrow failures. J Nippon Med Sch 2007;74:202-209
32. Ohyashiki K, Shay JW, Ohyashiki JH. Lack of mutations of the human telomerase RNA gene (hTERC) in myelodysplastic syndrome. Haematologica 2005;90:691 (Pubitemid 40780891)
33. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003;102:916-918 (Pubitemid 36917783)
34. Kirwan M, Vulliamy T, Marrone A, et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009;30: 1567-1573
35. Albin M, Bjork J, Welinder H, et al. Cytogenetic and morphologic subgroups of myelodysplastic syndromes in relation to occupational and hobby exposures. Scand J Work Environ Health 2003;29:378-387 (Pubitemid 37304272)
36. Ciccone G, Mirabelli D, Levis A, et al. Myeloid leukemias and myelodysplastic syndromes: chemical exposure, histologic subtype and cytogenetics in a case-control study. Cancer Genet Cytogenet 1993;68:135-139 (Pubitemid 23238706)
37. Rigolin GM, Cuneo A, Roberti MG, et al. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. Br J Haematol 1998;103:189-197 (Pubitemid 28470817)
38. West RR, Stafford DA, White AD, Bowen DT, Padua RA. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 2000;95: 2093-2097 (Pubitemid 30151650)